文献速递肝病

慢加急性肝衰竭3级患者肝移植后的长期结局

Long-term outcome following liver transplantation of patients with ACLF grade 3.
PubMed 文献 · J Hepatol · 2024-07-07

这项三中心回顾性法国研究纳入ACLF-3患者73例及匹配的ACLF-2、1和无ACLF对照,中位随访7.5年,发现ACLF-3患者5年和10年患者及移植物生存率与其他组无显著差异;ACLF-3患者5年生存率72.6%,高于定义肝移植物效用性的50%-70%阈值。

要点

  • ACLF-3患者肝移植后5年患者生存率为72.6%,与其他ACLF分级组无显著差异。
  • ACLF-3患者10年患者生存率为56.8%,与其他组无显著差异。
  • ACLF-3患者主要死因为感染(33.3%)和心血管事件(23.3%)。

核心结论

  • ACLF-3患者与匹配对照相比,5年和10年患者及移植物生存率无显著差异。
  • ACLF-3患者5年患者生存率高于定义肝移植物效用性的50%-70%阈值。
  • 作者认为应致力于基于合并症的选择以及感染和心血管事件的预防。

研究设计与样本

  • 三中心回顾性法国研究,纳入2017年发表的Princeps研究中的ACLF-3患者73例及匹配的ACLF-2(145例)、ACLF-1(119例)和无ACLF(292例)对照。
  • 探索5年和10年患者及移植物生存率、死因及其预测因素。

主要发现

  • ACLF-3患者中位随访7.5年,肝移植时中位MELD为40。
  • ACLF-3、ACLF-2、ACLF-1和无ACLF患者5年患者生存率分别为72.6%、69.7%、76.4%和77.0%(p=0.31)。
  • ACLF-3患者10年患者生存率为56.8%,与其他组无差异(p=0.37)。
  • ACLF-3患者主要死因为感染(33.3%)和心血管事件(23.3%)。
  • 排除早期死亡后,UCLA无效风险评分、年龄校正Charlson合并症指数和CLIF-C ACLF评分与10年患者生存独立相关;各组长期移植物生存率无差异;存活5年以上患者临床衰弱量表和WHO体能状态随时间改善。

关键数值与推荐

  • ACLF-3患者5年患者生存率为72.6%,10年患者生存率为56.8%。
  • ACLF-3患者中感染死因占33.3%,心血管事件死因占23.3%。

临床怎么用

  • 作者建议医生在决定是否移植这些患者时考虑合并症的累积负担。
  • 作者鼓励移植后采用个体化免疫抑制方案以降低感染风险,并长期严格控制心血管风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Utility, a major principle for allocation in the context of transplantation, is questioned in patients with acute-on-chronic liver failure grade 3 (ACLF-3) who undergo liver transplantation (LT). We aimed to explore long-term outcomes of patients included in a three-centre retrospective French study published in 2017. METHOD: All patients with ACLF-3 (n = 73), as well as their transplanted matched controls with ACLF-2 (n = 145), 1 (n = 119) and no ACLF (n = 292), who participated in the Princeps study published in 2017 were included. We explored 5- and 10-year patient and graft survival rates, causes of death and their predictive factors. RESULTS: Median follow-up of patients with ACLF-3 was 7.5 years. At LT, median MELD was 40. In patients with ACLF-3, 2, 1 and no ACLF, 5-year patient survival rates were 72.6% vs. 69.7% vs. 76.4% vs. 77.0%, respectively (p = 0.31). Ten-year patient survival for ACLF-3 was 56.8% and was not different to other groups (p = 0.37). Leading causes of death in patients with ACLF-3 were infections (33.3%) and cardiovascular events (23.3%). After exclusion of early death, UCLA futility risk score, age-adjusted Charlson comorbidity index and CLIF-C ACLF score were independently associated with 10-year patient survival. Long-term graft survival rates were not different across the groups. Clinical frailty scale and WHO performance status improved over time in patients alive after 5 years. CONCLUSION: 5- and 10-year patient and graft survival rates were not different in patients with ACLF-3 compared to matched controls. 5-year patient survival is higher than the 50%-70% threshold defining the utility of a liver graft. Efforts should focus on candidate selection based on comorbidities, as well as the prevention of infection and cardiovascular events. IMPACT AND IMPLICATIONS: While short-term outcomes following liver transplantation in the most severely ill patients with cirrhosis (acute-on-chronic liver failure grade 3 [ACLF-3]) are known, long-term data are limited, raising questions about the utility of graft allocation in the context of scarce medical resources. This study provides a favourable long-term update, confirming no differences in 5- and 10-year patient and graft survival following liver transplantation in patients with ACLF-3 compared to matched patients with ACLF-2, ACLF-1, and no-ACLF. The study highlights the risk of dying from infection and cardiovascular causes in the long-term and identifies scores including comorbidity evaluation, such as the age-adjusted Charlson comorbidity index, as independently associated with long-term survival. Therefore, physicians should consider the cumulative burden of comorbidities when deciding whether to transplant these patients. Additionally, after transplantation, the study encourages mitigating infectious risk with tailored immunosuppressive regimens and tightly managing cardiovascular risk over time.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Artru F, Sacleux SC, Ursic-Bedoya J, et al. Long-term outcome following liver transplantation of patients with ACLF grade 3. J Hepatol. 2024. PMID: 38981560. doi:10.1016/j.jhep.2024.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。